Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
linagliptin/metformin (Jentadueto®)
Reference No. 2446
Publication date:
14/08/2014
Appraisal information
linagliptin/metformin (Jentadueto®) 2.5 mg/1000 mg film-coated tablet
linagliptin/metformin (Jentadueto®) 2.5 mg/850 mg film-coated tablet
Company:
Boehringer Ingelheim Ltd
BNF category:
Endocrine system
NMG meeting date:
18/06/2014
AWMSG meeting date:
16/07/2014
Submission Type:
Limited Submission
Status:
Recommended
Advice No:
2114
Ratification by Welsh Government:
13/08/2014
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
Linagliptin/metformin (Jentadueto®) is recommended as an option for use within NHS Wales for the treatment of adult patients with type 2 diabetes mellitus in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control when insulin and metformin alone do not provide adequate glycaemic control.
Final Appraisal Recommendation (FAR)
Download
linagliptin-metformin (Jentadueto) 2446 FAR
AWMSG Secretariat Appraisal Report (ASAR)
Download
linagliptin-metformin (Jentadueto) 2446 ASAR
Clinical Expert (CE) Summary
Download
linagliptin-metformin (Jentadueto) 2446 CE Summary